Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern india

✍ Scribed by Sayan Mitra; Nilabja Sikdar; Chaitali Misra; Shalini Gupta; Ranjan Rashmi Paul; Bidyut Roy; Chinmay Kumar Panda; Susanta Roychoudhury

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: French
• Weight: 114 KB
• Volume: 117
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.21263

✦ Synopsis

Abstract

The role of 3 p53 polymorphisms (16 bp duplication at intron 3, codon 72 Arg/Pro and intron 6 __Nci__I RFLP at np 13494) as potential markers for indicating cancer risk remains inconclusive. In our case‐control study consisting of 197 leukoplakia and 310 oral squamous cell carcinoma (SCC) patients and 348 controls, genotype frequencies at these 3 p53 loci were determined by PCR‐RFLP method and analyzed by multiple logistic regression to determine the risks of the diseases. The 2/2 genotype at codon 72 of p53 was at risk for developing leukoplakia (OR = 1.6, 95% CI 1.1–2.3), whereas the combination of 1/2 and 2/2 genotypes at intron 3 and 1/1 and 1/2 genotypes at intron 6 conferred a protective effect against leukoplakia and oral SCC development, respectively (OR = 0.5, 95% CI 0.4–0.8 and OR = 0.6, 95% CI 0.5–0.9, respectively). When subjects were stratified according to specific tobacco habit, the risk/protection estimates improved significantly in some cases. Specifically, the exclusive smokers with p53 codon 72 2/2 genotype showed a higher risk of developing leukoplakia (OR = 2.7, 95% CI 1.2–6.3). Furthermore, a particular p53 haplotype 1‐2‐2 was at risk for both tobacco‐associated leukoplakia and oral SCC (OR = 1.5, 95% CI 1.1–1.9 and OR = 1.3, 95% CI 1.1–1.7, respectively). Our results show that both specific p53 genotype and haplotype can indicate risk of tobacco‐associated leukoplakia, but risk of development of tobacco‐associated oral SCC can be predicted by specific p53 haplotype only. © 2005 Wiley‐Liss, Inc.